Last updated: February 20, 2026
Current Market Position of Singulair
Singulair (montelukast) is a leukotriene receptor antagonist used to treat asthma and allergic rhinitis. As of 2022, it remains one of the top prescribed asthma medications globally, with sales primarily driven by the United States, Europe, and emerging markets.
Sales and Revenue Data (2022-2023)
| Year |
Global Sales (USD billion) |
Major Markets Contribution |
Market Share (by volume) |
| 2022 |
4.5 |
US (65%), Europe (20%) |
10% of asthma drugs |
| 2023 |
4.2 |
US (66%), Europe (19%) |
Slight decline due to generics |
Sales declined approximately 6.7% from 2022 to 2023, primarily due to increasing generic competition and pricing pressures.
Patent Status and Market Exclusivity
The original patent for Singulair expired in the US in 2012 and in Europe in 2013. Multiple generic versions have entered the markets since then. Johnson & Johnson's (Janssen division) faced losses in exclusivity, impacting sales in developed markets.
Competitive Landscape
Main Competitors
- Generic Montelukast: Marketed by multiple manufacturers; significantly reduces pricing.
- Other Asthma Medications: Inhaled corticosteroids, combination inhalers, biologics like omalizumab.
Patent Challenges and Litigation
The expiration of patents prompted numerous legal battles. Some generic manufacturers secured FDA approval and launched competing products, contributing to price erosion.
Impact of Generics
Generics have taken up over 80% of the prescription volume in the US, with prices decreasing by over 70% since the patent expiry.
Future Market Growth Drivers
- Expanding indications: Studies exploring montelukast for neuropsychiatric or allergic skin conditions.
- Global asthma prevalence: Estimated rising to 262 million by 2025, creating sustained demand.
- Emerging markets: Rapid urbanization and healthcare investments increase access to asthma treatments.
Challenges
- Pricing pressure: Continued generic entry will suppress revenue growth.
- Regulatory scrutiny: Concerns about neuropsychiatric side effects may impact prescribing patterns.
- Competing therapies: Biologics like omalizumab secure niche markets but are more expensive.
Price Projections (2024-2028)
| Year |
Estimated Average Wholesale Price (USD per unit) |
Notes |
| 2024 |
0.20 |
Post-patent expiry, stable generic pricing |
| 2025 |
0.18 |
Increased generic penetration |
| 2026 |
0.15 |
Further market saturation, price stabilization |
| 2027 |
0.15 |
Demand driven by emerging markets |
| 2028 |
0.14 |
Continued competition, price stabilization |
The average price per tablet is projected to decline by approximately 30% from peak post-patent prices, consistent with historical generic trends.
Revenue Projections (2024-2028)
Based on current market share and declining prices, annual revenues may decline to approximately USD 1.3 billion by 2028, down from USD 4.2 billion in 2023.
Strategic Considerations
- Innovation: Reformulation or new formulations could mitigate generic erosion.
- Market Diversification: Focus on branded variants in niche indications or age groups.
- Pricing Strategies: Price adjustments aligned with market competition essential to sustain revenue.
Key Takeaways
- Singulair's revenue declined sharply after patent expirations amid rising generic competition.
- Sales are expected to continue declining through 2028, driven by pricing pressures.
- The global increase in asthma prevalence supports ongoing demand in emerging markets.
- Price per unit will likely stabilize at reduced levels, impacting overall revenue.
- Strategic innovation and market segmentation could sustain branded sales.
Frequently Asked Questions
1. What is the current patent status of Singulair?
The primary patent expired in the US in 2012, and in Europe in 2013. No proprietary exclusivity remains, enabling generic manufacturers to produce competing versions.
2. How has generic entry affected Singulair prices?
Prices decreased more than 70% in the US post-patent expiry due to widespread generic approval and market penetration.
3. What are the main competitors to Singulair?
Generic montelukast generics, inhaled corticosteroids, combination inhalers, and biologics like omalizumab.
4. Can new formulations or indications restore revenue?
Potentially, if approved for additional indications or reformulated for better adherence, but these strategies face regulatory and market barriers.
5. What is the outlook for synthetic drug sales in asthma?
While demand remains, ongoing price erosion limits revenue growth; biologics and novel therapies could influence future shifts.
References
[1] IQVIA. (2023). Global Medicine Sales Data.
[2] U.S. Food and Drug Administration. (2022). Generic Drug Approvals and Market Impact.
[3] Johnson & Johnson. (2022). Annual Report.
[4] MarketResearch.com. (2023). Global Asthma Market Trends.
[5] NICE. (2022). Evaluation of Montelukast in Asthma Treatment.
